More Videos
SPECIAL REPORT
MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- US Home Prices Up 5th Month, 2nd Straight Quarter
- GM's Agreement to Sell Saab To Swedish Firm Falls Apart
- FDIC Fund Falls into The Red, Bair Urges Lending
- Buyers Look For Bargains At Luxury Condo Auction
- Weak Dollar Is Golden for Mining Companies
- Revised GDP Reading Puts Growth at 2.8%; Inflation Tame
- 10 Holiday Cocktail Recipes from Top Mixologists
- Behind The Scenes With Warren Buffett
- CA "More Profitable" After Saving Energy: CEO
- Novartis 'Cells' Its Flu Vaccine Technology
- Silicon Valley and Hollywood Now Fast Friends
- Markets Can Rise 5-10% in the Near-Term: Strategist
- Busch: The Debt-Interest Rate Paradox
- The Lloyd's Prayer, Leggo My Eggo, Plate Hate & Your Emails
- Buy These 'Competitively Positioned' Stocks: Portfolio Manager
- Behind The Scenes With Warren Buffett
- 'Why the American Consumer Will Keep on Buying No Matter What'
- On Assignment: Europe & Asia
- $42 Billion US Bond Auction Receives Strong Demand
- GM's Agreement to Sell Saab Unit Falls Apart
- Consumer Confidence Improves but Still Shaky
- US Home Prices Up 5th Month, 2nd Straight Quarter
- FDIC Fund Falls into The Red, Bair Urges Lending
- Six Ways to Boost Your Income in a Big Way
- Buyers Look for Bargains at Luxury Condo Auction
- Ron Paul's Plan to Audit Fed a 'Serious Attack': Mishkin
- Strong Banks, Weak Credit: Treasury Rethinks TARP
PHARMA'S MARKET VIDEO
Novartis Opens 1st US Plant for Flu Vaccine 
6 hrs agoCholesterol Drug Battle: Niaspan vs. Zetia 16 Nov 2009
Cardiologist Grades Cholesterol Drug Study 16 Nov 2009
Merck's Cholesterol Drugs Under Pressure 16 Nov 2009
Cholesterol Drug Battle: Merck vs. Abbott Labs 16 Nov 2009
Cholesterol Drug Battle 16 Nov 2009
RSS FEED
Pharma's Market
Text Size 
 |
] put out a press release this morning announcing that an unidentified institutional investor is going to buy eight million shares and warrants to buy as much as another eight million for a total infusion of $47 million. DNDN says it will use the money to "fund our commercialization activities for Provenge," among other things. Provenge is a therapeutic vaccine for prostate cancer that is in the middle of a crucial clinical trial.
Back in February I blogged about Morgan Stanley and a hedge fund, Visium Asset Management, taking a combined 16.5 percent stake in DNDN. Big investors like that have 45 days to disclose their positions to the Securities and Exchange Commission, so the identity of Dendreon's secret lover could be revealed in the not-too-distant future.
Dendreon can be a very volatile stock. It has a huge short interest or shares that belong to investors who are hoping the price will fall. This is not an investment for the faint of heart. But obviously another one of the "big boys" has a strong ticker.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes